Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.

  • 4D Molecular Therapeutics' Income from Continuing Operations fell 2968.16% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 4583.13%. This contributed to the annual value of -$160.8 million for FY2024, which is 5974.31% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Income from Continuing Operations stood at -$56.9 million for Q3 2025, which was down 2968.16% from -$54.6 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Income from Continuing Operations high stood at -$7.6 million for Q2 2021, and its period low was -$56.9 million during Q3 2025.
  • Its 5-year average for Income from Continuing Operations is -$31.6 million, with a median of -$28.7 million in 2023.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Income from Continuing Operations soared by 6070.82% in 2023 and then plummeted by 33416.52% in 2024.
  • 4D Molecular Therapeutics' Income from Continuing Operations (Quarter) stood at -$25.1 million in 2021, then dropped by 9.2% to -$27.4 million in 2022, then decreased by 17.86% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then fell by 14.51% to -$56.9 million in 2025.
  • Its Income from Continuing Operations stands at -$56.9 million for Q3 2025, versus -$54.6 million for Q2 2025 and -$48.0 million for Q1 2025.